The discovery and status of sibutramine as an anti-obesity drug (Q34128195)

31 July 2017

1 reference

title

The discovery and status of sibutramine as an anti-obesity drug (English)

1 reference

31 July 2017

0 references

1 reference

Carla A Luque

1

1 reference

PubMed ID

12007530

31 July 2017

Jose A Rey

series ordinal

2

1 reference

PubMed ID

12007530

31 July 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

European Journal of Pharmacology

31 July 2017

1 reference

31 July 2017

440

1 reference

31 July 2017

2-3

1 reference

31 July 2017

119-128

1 reference

Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Absence of cardiac valve dysfunction in obese patients treated with sibutramine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Sibutramine, a serotonin uptake inhibitor, increases dopamine concentrations in rat striatal and hypothalamic extracellular fluid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Reciprocal relation of food intake and sympathetic activity: experimental observations and clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

[3H]paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: effect of administration of various antidepressant treatments.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

D1 receptor binding in rat striatum: modification by various D1 and D2 antagonists, but not by sibutramine hydrochloride, antidepressants or treatments which enhance central dopaminergic function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

[3H]nisoxetine--a radioligand for noradrenaline reuptake sites: correlation with inhibition of [3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Sibutramine does not decrease the number of 5-HT re-uptake sites in rat brain and, like fluoxetine, protects against the deficits produced by dexfenfluramine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Thermogenic effects of sibutramine and its metabolites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Valvular heart disease associated with fenfluramine-phentermine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Sibutramine and thermogenesis in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Dexfenfluramine. An updated review of its therapeutic use in the management of obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Thermogenic effects of sibutramine in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Antidepressant treatments, including sibutramine hydrochloride and electroconvulsive shock, decrease beta 1- but not beta 2-adrenoceptors in rat cortex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Effects of antidepressant drugs and electroconvulsive shock on pre- and postsynaptic α2-adrenoceptor function in the brain: rapid down-regulation by sibutramine hydrochloride

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: evidence that dopamine is not a pharmacological target for sibutramine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

A comparison of various antidepressant drugs demonstrates rapid desensitisation of alpha 2-adrenoceptors exclusively by sibutramine hydrochloride.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Comparative study of fluoxetine, sibutramine, sertraline, and dexfenfluramine on the morphology of serotonergic nerve terminals using serotonin immunohistochemistry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Phenylpropanolamine and the risk of hemorrhagic stroke

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Clinical pharmacology of sibutramine hydrochloride (BTS 54524), a new antidepressant, in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Effect on radiolabelled-monoamine uptake in vitro of plasma taken from healthy volunteers administered the antidepressant sibutramine HCl

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Characterization of 8-OH-DPAT-induced hypothermia in mice as a 5-HT1A autoreceptor response and its evaluation as a model to selectively identify antidepressants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Dexfenfluramine. A review of its pharmacological properties and therapeutic potential in obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Sibutramine reduces food intake in non-dieting women with obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Abuse liability assessment of sibutramine, a novel weight control agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

The effects of BTS 54,505, a metabolite of sibutramine, on monoamine and excitatory amino acid-evoked responses in the rat dorsolateral geniculate nucleus in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Effects of sibutramine on resting metabolic rate and weight loss in overweight women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Appetite suppressants. A review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Influence of sibutramine on energy expenditure in African American women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901423-1

10.1016/S0014-2999(02)01423-1

7 January 2021

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

12007530